Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Phreesia

BST:19P
Snowflake Description

Adequate balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
19P
BST
$1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
19P Share Price and Events
7 Day Returns
0%
BST:19P
5.2%
DE Healthcare Services
1.4%
DE Market
1 Year Returns
-
BST:19P
5%
DE Healthcare Services
3.7%
DE Market
19P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Phreesia (19P) 0% 0% -2.8% - - -
DE Healthcare Services 5.2% 7.6% -19.4% 5% 38.1% 186%
DE Market 1.4% 1.8% 3.4% 3.7% 8.3% 22.9%
1 Year Return vs Industry and Market
  • No trading data on 19P.
  • No trading data on 19P.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Phreesia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Phreesia to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Phreesia.

BST:19P Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:19P
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.04
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.04 (1 + (1- 21%) (2.38%))
1.04
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.04 * 5.96%)
6.43%

Discounted Cash Flow Calculation for BST:19P using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Phreesia is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BST:19P DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.43%)
2020 -5.30 Analyst x2 -4.98
2021 -7.01 Analyst x4 -6.19
2022 0.89 Analyst x3 0.73
2023 7.00 Analyst x1 5.46
2024 11.35 Est @ 62.15% 8.31
2025 16.30 Est @ 43.57% 11.22
2026 21.28 Est @ 30.57% 13.76
2027 25.84 Est @ 21.47% 15.70
2028 29.75 Est @ 15.09% 16.98
2029 32.91 Est @ 10.63% 17.66
Present value of next 10 years cash flows $78.00
BST:19P DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $32.91 × (1 + 0.23%) ÷ (6.43% – 0.23%)
$532.25
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $532.25 ÷ (1 + 6.43%)10
$285.55
BST:19P Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $78.00 + $285.55
$363.55
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $363.55 / 35.76
$10.17
BST:19P Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:19P represents 0.75294x of NYSE:PHR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.75294x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 10.17 x 0.75294
€7.65
Value per share (EUR) From above. €7.65
Current discount Discount to share price of €21.11
= -1 x (€21.11 - €7.65) / €7.65
-175.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Phreesia is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Phreesia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Phreesia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:19P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-07-31) in USD $-35.45
NYSE:PHR Share Price ** NYSE (2019-07-22) in USD $28.03
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.18x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 19.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Phreesia.

BST:19P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:PHR Share Price ÷ EPS (both in USD)

= 28.03 ÷ -35.45

-0.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Phreesia is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Phreesia is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Phreesia's expected growth come at a high price?
Raw Data
BST:19P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
70.5%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 1.81x
Germany Market PEG Ratio Median Figure of 266 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Phreesia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Phreesia's assets?
Raw Data
BST:19P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-07-31) in USD $2.88
NYSE:PHR Share Price * NYSE (2019-07-22) in USD $28.03
Germany Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 1.95x
Germany Market PB Ratio Median Figure of 599 Publicly-Listed Companies 1.76x
BST:19P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:PHR Share Price ÷ Book Value per Share (both in USD)

= 28.03 ÷ 2.88

9.75x

* Primary Listing of Phreesia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Phreesia is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Phreesia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Phreesia has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Phreesia expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
70.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Phreesia expected to grow at an attractive rate?
  • Unable to compare Phreesia's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Phreesia's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Phreesia's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:19P Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:19P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 70.5%
BST:19P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 18.2%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 12%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:19P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:19P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-01-31 203 1
2022-01-31 174 11 -4 5
2021-01-31 144 2 -12 6
2020-01-31 119 1 -44 5
2019-10-19
BST:19P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-07-31 110 0 -113
2019-04-30 104 1 -54
2019-01-31 100 -2 -45
2018-01-31 80 -11 -38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Phreesia is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Phreesia's revenue is expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:19P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Phreesia Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:19P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-01-31
2022-01-31 -0.23 -0.23 -0.23 2.00
2021-01-31 -0.39 -0.37 -0.41 3.00
2020-01-31 -6.54 -0.56 -12.53 2.00
2019-10-19
BST:19P Past Financials Data
Date (Data in USD Millions) EPS *
2019-07-31 -35.45
2019-04-30 -28.26
2019-01-31 -24.53
2018-01-31 -24.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Phreesia will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Phreesia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Phreesia has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Phreesia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Phreesia's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Phreesia does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Phreesia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Phreesia's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Phreesia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Phreesia Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:19P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-07-31 110.36 -113.04 53.58 17.05
2019-04-30 104.33 -54.11 49.21 15.54
2019-01-31 99.89 -45.26 46.44 14.35
2018-01-31 79.83 -38.17 43.60 11.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Phreesia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Phreesia has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Phreesia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Phreesia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Phreesia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Phreesia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Phreesia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Phreesia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Phreesia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Phreesia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Phreesia Company Filings, last reported 2 months ago.

BST:19P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-07-31 102.85 19.21 100.05
2019-04-30 -9.71 34.23 5.91
2019-01-31 -4.48 28.02 1.54
2018-01-31 8.61 20.62 10.50
  • Phreesia's level of debt (18.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Phreesia's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Phreesia has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Phreesia has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Phreesia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Phreesia has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Phreesia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Phreesia dividends.
If you bought €2,000 of Phreesia shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Phreesia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Phreesia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:19P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 338 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:19P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-01-31
2022-01-31
2021-01-31
2020-01-31
2019-10-19

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Phreesia has not reported any payouts.
  • Unable to verify if Phreesia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Phreesia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Phreesia has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Phreesia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Phreesia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Phreesia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Phreesia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chaim Indig
COMPENSATION $510,249
AGE 41
TENURE AS CEO 4.8 years
CEO Bio

Mr. Chaim Indig Co-Founded Phreesia, Inc. in 2005 and serves as its Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under his leadership, Phreesia has established a broad national footprint, developed strategic partnerships with some of the world’s largest healthcare companies and earned accolades for its role in generating workplace efficiencies and improving clinical care. He has earned widespread recognition, most recently with the 2011 TripleTree I Award, and it was named Health Management Technology s Coolest Product of 2010. Prior to founding Phreesia, he led the successful introduction of high-end analytics software company Spotfire into the American pharmaceutical marketing space. He was also an integral member of the original team at Olap@Work, the leader in SQL server front-end tools. He has become a trusted industry expert and speaker, and is recognized as a prominent business leader. In 2011, he was a finalist for Ernst & Young s Entrepreneur of the Year Award, and he was featured in the Stanford Social Innovation Review as an innovator in the healthcare field.

CEO Compensation
  • Insufficient data for Chaim to compare compensation growth.
  • Chaim's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Phreesia management team in years:

4.8
Average Tenure
44.5
Average Age
  • The tenure for the Phreesia management team is about average.
Management Team

Chaim Indig

TITLE
Co-Founder
COMPENSATION
$510K
AGE
41
TENURE
4.8 yrs

Evan Roberts

TITLE
Co-Founder & COO
COMPENSATION
$380K
AGE
40
TENURE
14.8 yrs

Tom Altier

TITLE
Chief Financial Officer
COMPENSATION
$380K
AGE
69
TENURE
6.8 yrs

Charles H. Kallenbach

TITLE
General Counsel & Secretary
COMPENSATION
$421K
AGE
56
TENURE
3 yrs

Daniel Nathan

TITLE
Chief Technology Officer
AGE
43
TENURE
0.7 yrs

Will Rideout

TITLE
Vice President of Sales
TENURE
8.6 yrs

Michael Davidoff

TITLE
Senior Vice President of Marketing & Business Development
AGE
46
TENURE
0.8 yrs

Amy VanDuyn

TITLE
Senior Vice President of Human Resources
AGE
46
TENURE
9.5 yrs

Ralph Gonzales

TITLE
Chief Medical Advisor

David Linetsky

TITLE
Senior Vice President of Life Sciences
AGE
39
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Phreesia board of directors in years:

4.8
Average Tenure
57
Average Age
  • The tenure for the Phreesia board of directors is about average.
Board of Directors

Michael Weintraub

TITLE
Chairman
COMPENSATION
$343K
AGE
57
TENURE
14.8 yrs

Chaim Indig

TITLE
Co-Founder
COMPENSATION
$510K
AGE
41
TENURE
4.8 yrs

Mark Smith

TITLE
Director
COMPENSATION
$186K
AGE
68
TENURE
1 yrs

Gillian Munson

TITLE
Director
AGE
48
TENURE
0.4 yrs

Ed Cahill

TITLE
Director
AGE
66
TENURE
12 yrs

Elsa-Grace Giardina

TITLE
Member of Medical Advisory Board

Richard Jackson

TITLE
Member of Medical Advisory Board

Mark Blais

TITLE
Member of Medical Advisory Board

Michael Brodman

TITLE
Member of Medical Advisory Board

Lee Schwamm

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Phreesia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Phreesia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company’s Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, including through Phreesia Mobile, a patients’ mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company’s Phreesia Platform provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients, healthcare provider organizations, and life sciences companies. The company was founded in 2005 and is headquartered in New York, New York.

Details
Name: Phreesia, Inc.
19P
Exchange: BST
Founded: 2005
$899,846,682
35,761,374
Website: http://www.phreesia.com
Address: Phreesia, Inc.
432 Park Avenue South,
12th Floor,
New York,
New York, 10016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE PHR Common Stock New York Stock Exchange US USD 18. Jul 2019
DB 19P Common Stock Deutsche Boerse AG DE EUR 18. Jul 2019
BST 19P Common Stock Boerse-Stuttgart DE EUR 18. Jul 2019
Number of employees
Current staff
Staff numbers
436
Phreesia employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/10/19 22:17
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/10/10
Last earnings filing: 2019/09/10
Last earnings reported: 2019/07/31
Last annual earnings reported: 2019/01/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.